In the Claims:

1. (currently amended) ~~Active~~ An active substance combination ~~consisting of~~ comprising deoxypeganine or one of its pharmaceutically acceptable derivatives and mecamylamine or one of its pharmaceutically acceptable derivatives for the production of a medicament for treating alcohol abuse and/or alcohol dependence.

2. (currently amended) ~~Active~~ The active substance combination according to claim 1, ~~characterized in that~~ wherein the pharmaceutically acceptable derivative of deoxypeganine is selected from the group consisting of deoxypeganine hydrochloride, 7-bromodeoxypeganine, 7-bromo-6-hydroxy-5-methoxydeoxypeganine, 7-chloro-6-hydroxy-5-methoxydeoxypeganine, 7-fluoro-6-hydroxy-5-methoxydeoxypeganine and 7-iodo-6-hydroxy-5-methoxydeoxypeganine.

3. (currently amended) ~~Active~~ The active substance combination according to claim 1, wherein ~~or 2, characterized in that~~ the pharmaceutically acceptable derivative of mecamylamine is selected from the group consisting of the salts of mecamylamine with halogen acids [[or]] and simple organic acids ~~such as tartaric acid, succinic acid, maleic acid and the like~~.

4. (currently amended) ~~Active~~ The active substance combination according to claim 1, wherein ~~any one of the preceding claims, characterized in that~~ mecamylamine is present in a [[the]] form selected from the group consisting of the racemic mixture of [[its]] the two stereoisomers of mecamylamine and ~~or in the form of~~ one of [[its]] the two stereoisomers of mecamylamine.

5. (currently amended) ~~Active~~ The active substance combination according to claim 1, wherein ~~any one of the preceding claims, characterized in that~~ the medicament is in the form of a combined administration form for deoxypeganine or one of its pharmaceutically acceptable derivatives and mecamylamine or one of its pharmaceutically acceptable derivatives.

6. (currently amended) ~~Active~~ The active substance combination according to ~~any one of claims~~ claim 1, wherein ~~to 4, characterized in that~~ the medicament is in the form of separate administration forms for deoxypeganine or one of its pharmaceutically acceptable derivatives and mecamylamine or one of its pharmaceutically acceptable derivatives.

7. (currently amended) ~~Active~~ The active substance combination according to claim 1, wherein ~~any one of the preceding claims, characterized in that~~ the medicament is in the form of an administration form to be administered orally or parenterally~~,~~

~~preferably transdermally~~.

8. (currently amended) ~~Active~~ The active substance combination according to claim 7, wherein said medicament ~~characterized in that it~~ is in the form of a medicament having a depot effect.

9. (currently amended) ~~Active~~ The active substance combination according to claim 1, wherein ~~any one of the preceding claims, characterized in that the~~ an administration form for a daily dose comprises 50 to 750 mg of deoxypeganine or one of its pharmaceutically acceptable salts in the case of an administration form to be administered orally ~~is 50 to 750 mg, preferably 100 to 400 mg~~.

10. (currently amended) ~~Active~~ The active substance combination according to ~~any one of claims~~ claim 1, wherein ~~to 8, characterized in that the~~ an administration form for a daily dose comprises 50 to 250 mg of deoxypeganine or one of its pharmaceutically acceptable salts in the case of an administration form to be administered transdermally ~~is 50 to 250 mg~~.

11. (currently amended) ~~Active~~ The active substance combination according to claim 1, wherein an administration form for a ~~any one of the preceding claims, characterized in that the~~ daily dose comprises 2.5 to 20 mg of mecamylamine in the case of an administration form to be administered orally ~~is 2.5 to 20 mg, preferably 2.5 to 7.5 mg~~.

12. (currently amended) ~~Active~~ The active substance combinations according to ~~any one of claims~~ claim 1, wherein an administration form for a ~~to 10, characterized in that the~~ daily dose comprises 0.5 to 10 mg of mecamylamine in the case of an administration form with delayed release ~~is 0.5 to 10 mg~~.

13. (currently amended) [[Use of]] The treatment of alcohol abuse and/or alcohol dependencies comprising administrating comprising deoxypeganine or one of its pharmaceutically acceptable derivatives and mecamylamine or one of its pharmaceutically acceptable derivatives ~~an active substance combination according to any one of the preceding claims for treating alcohol abuse and/or alcohol dependence~~.

14. (currently amended) ~~Process~~ A process for treating alcohol abuse and/or alcohol dependence, comprising the steps of administrating ~~characterized by the administration of~~ an active substance combination comprising deoxypeganine or one of its pharmaceutically acceptable derivatives and mecamylamine or one of its pharmaceutically acceptable derivatives ~~according to any one of claims 1 to 12~~.

15. (currently amended) ~~Process~~ The process according to claim 14, ~~characterized in~~

~~that the administration of~~ further comprising the step of pre-treatment with mecamylamine before administrating the active substance combination ~~is preceded by a pre-treatment with mecamylamine~~.

16. (new) The active substance combination according to claim 3, wherein said simple organic acids are selected from the group consisting of tartaric acid, succinic acid and maleic acid.

17. (new) The active substance combination according to claim 7, wherein the medicament is in the form of an administration form to be administered transdermally.

18. (new) The active substance combination according to claim 9, wherein the daily dose of deoxypeganine or one of its pharmaceutically acceptable salts in the case of an administration form to be administered orally is 100 to 400 mg.

19. (new) The active substance combination according to claim 11, wherein the daily dose of mecamylamine in the case of an administration form to be administered orally is 2.5 to 7.5 mg.

20. (new) The process according to claim 15, wherein the pre-treatment step comprises daily doses of between 0.5 and 29 mg of racemic mecamylamine or the individual isomers of mecamylamine and wherein the pre-treatment step lasts between 1 and 5 days.